US 2007/0185012 A1 · Glycopeptides for the treatment of als and other metabolic and autoimmune disorders

Abstract

New compositions and methods for treating patients suffering from Amyotrophic Lateral Sclerosis (ALS) and other metabolic and autoimmune disorders, which include glycopeptides such as N-acetyl-D-glucosaminyl(β1-4)-N-Acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and peptide analog-L-alanyl-D-glutamic acid (GMDP-A) of at least 98% purity administered either alone, or in combination with a flavone such as luteolin and/or an isoflavone such as genistein, optionally in combination with a flavonol glycoside such as isoquercitrin or rutin. The high purity glycopeptides have a decreased amount immunogenic impurities and demonstrate a synergistic effect when combined with luteolin and/or genistein in presence of isoquercitrin.

Claims15

Dependent claims

A method for treating a metabolic or autoimmune disorder in a human or veterinary patient, said method comprising the steps of

(A) administering to the patient a therapeutically effective amount of a compound having the formula:
wherein:
R1, R2 and R3 each represents a hydrogen atom or a C1-C22 acyl group;
R4 represents a hydrogen atom or a C1-C6 alkyl group;
R5 represents a C1-C2, alkyl group or a C6 or C,0 aryl group;
R6 represents a hydrogen atom;
and
R represents the residue of an amino acid or a linear peptide of up to from 2 to 6 amino acid residues. Furthermore, at least one of the residues may be optionally substituted with a lipophilic group through an ester or amide bond;
and n is 1 and 2;
and
(B) administering to the patient a natural or synthetic compound that comprises a flavone, flavonoid, isoflavone or a derivative, prodrug or congener thereof.

8 more elements

Dependencies are inferred from the claim text.

Glycopeptides for the treatment of als and other metabolic and autoimmune disorders

Life of this patent

Glycopeptides for the treatment of als and other metabolic and autoimmune disorders

Life of this patent

Abstract

Claims15